Compounds > 2,4,6,2',4',6'-hexachlorobiphenyl
Page last updated: 2024-12-06
2,4,6,2',4',6'-hexachlorobiphenyl
Description
2,4,6,2',4',6'-hexachlorobiphenyl (PCB 153) is a highly chlorinated polychlorinated biphenyl (PCB) congener. It is a persistent organic pollutant (POP) and is known for its resistance to environmental degradation. PCBs were widely used in industrial applications due to their fire-retardant and insulating properties, but their production and use were phased out due to their toxicity and environmental persistence. PCB 153, like other PCBs, is a known endocrine disruptor, meaning it can interfere with the hormone systems of living organisms. It has been linked to reproductive problems, developmental defects, and immune system suppression. PCB 153 is bioaccumulative, meaning it can build up in the food chain, reaching high concentrations in top predators. Due to its widespread environmental contamination and potential health risks, PCB 153 is extensively studied to understand its fate and transport in the environment, its effects on wildlife and human health, and to develop strategies for remediation and risk management.'
2,2',4,4',6,6'-hexachlorobiphenyl : A hexachlorobiphenyl that is biphenyl in which both of the phenyl rings are substituted at positons 2, 4, and 6 by chlorines. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
PubMed CID | 36647 |
CHEBI ID | 34203 |
SCHEMBL ID | 2937097 |
MeSH ID | M0088893 |
Synonyms (30)
Synonym |
CHEBI:34203 , |
2,2',4,4',6,6'-hexachloro-1,1'-biphenyl |
2,4,6,2',4',6'-hexachlorobiphenyl |
2,2',4,4',6,6'-hcb |
2,2',4,4',6,6'-hexachlorodiphenyl |
biphenyl, 2,2',4,4',6,6'-hexachloro- |
brn 2058693 |
einecs 251-773-8 |
pcb 155 |
33979-03-2 |
inchi=1/c12h4cl6/c13-5-1-7(15)11(8(16)2-5)12-9(17)3-6(14)4-10(12)18/h1-4 |
2,2',4,4',6,6'-hexachlorobiphenyl |
1,1'-biphenyl, 2,2',4,4',6,6'-hexachloro- |
1,3,5-trichloro-2-(2,4,6-trichlorophenyl)benzene |
unii-r9yk3084vs |
r9yk3084vs , |
hexachlorobiphenyl, 2,4,6,2',4',6'- |
SCHEMBL2937097 |
ICOAEPDGFWLUTI-UHFFFAOYSA-N |
DTXSID3040302 , |
pcb no. 155 |
pcb no. 155 10 microg/ml in isooctane |
Q27115900 |
5-(3-(tert-butyl)-1-(cyclopropylmethyl)ureido)-n,n-diethyl-1,3,4-thiadiazole-2-sulfonamide |
CS-0451372 |
SY250283 |
mfcd00152541 |
2,2 inverted exclamation mark ,4,4 inverted exclamation mark ,6,6 inverted exclamation mark -hexachlorobiphenyl |
246-hcb |
dtxcid1020302 |
Drug Classes (2)
Class | Description |
hexachlorobiphenyl | Any polychlorobiphenyl with molecular formula C12H4Cl6. |
trichlorobenzene | Any member of the class of chlorobenzenes carrying three chloro substituents at unspecified positions. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (12)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 2 (16.67) | 18.7374 |
1990's | 2 (16.67) | 18.2507 |
2000's | 4 (33.33) | 29.6817 |
2010's | 3 (25.00) | 24.3611 |
2020's | 1 (8.33) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.10
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.10 (24.57) | Research Supply Index | 2.56 (2.92) | Research Growth Index | 4.66 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 12 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |